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Abstract 
 
 
 
DEVELOPMENT AND IMPLEMENTATION OF A TISSUE SPECIFIC MICRORNA 
PREDICTION TOOL FOR IDENTIFYING TARGETS OF THE TUMOR 
SUPPRESSOR MICRORNA-17-3P 
 
 A unique computational approach was undertaken to identify targets of miR-17-3p 
that impart an oncogenic potential to the cells of the prostate. Utilizing this approach, we 
identified insulin growth factor receptor 1 (IGF1R) as a potential target of miR-17-3p. 
IGF1R imparts an oncogenic approach to the cells by helping cells escape apoptosis, 
become hypertrophic and increase the production of extracellular proteases that allow cells 
to detach from neighbors.  
The regulation of insulin growth factor receptor 1 by human microRNA-17-3p was 
evaluated using a western blot analysis of prostate cancer cell lines. Protein levels were 
compared in a cell line that expressed a non-targeting control RNA and a cell line that 
expressed microRNA-17-3p. The cell line that expressed the non-targeting control had 
significantly higher levels of IGF1R protein than the cell line expressing more of the active 
microRNA. Based on this experiment, it appears that microRNA-17-3p might regulate the 
insulin growth factor receptor 1.  
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Chapter 1: 
Introduction 
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The Prostate Gland 
 
 The male prostate gland is a walnut shaped exocrine gland about four centimeters 
in diameter and has a mass of approximately 20 grams when fully mature. The prostate is 
located inferior to the urinary bladder, and anterior to the rectum. Passing through the prostate is 
the prostatic urethra. In boys, the prostate gland is very small and begins to hypertrophy as they 
approach adolescence and reaches its mature size shortly after puberty. Under normal 
circumstances, the prostate gland ceases to grow. In half of all men, when they reach an 
approximate age of fifty, the gland begins to hypertrophy again. This results in a condition 
known as benign prostatic hypertrophy (BPH). During the progression of BPH, the prostate 
gland begins to compress the urethra and causes great difficulty in urination. Many men over the 
age of fifty suffer from increased frequency of urination, hesitancy and urinary incontinence.  
This prostate gland serves several important functions in the male genitourinary system. 
Secretions of the prostate account for approximately two thirds of the fluid content of semen. 
They include an alkalinic substance that counteracts the acidity of the vagina allowing sperm 
cells to survive the harsh environment that they encounter on their journey to the mature ovum.  
The prostate gland is composed in part of smooth muscle that contracts when stimulated 
increasing the velocity of ejaculate through the urethra. During ejaculation the prostate gland 
will contract and block the flow of urine into the urethra during ejaculation by closing off the 
portion of the urethra coming from the urinary bladder.   
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Incidence of Prostate Cancer 
 
Cancer of the prostate gland is the second leading cause of cancer related deaths in men 
in the United States [1]. In 2009, it is estimated that nearly 193,000 men were diagnosed with 
cancer of the prostate gland and nearly 27,000 of them will die because of this cancer [2].  
Nearly one in every six men will develop cancer of the prostate gland in his lifetime. Prostate 
cancer is a significant problem in the United States not only because of the numbers of men 
affected but also the cost of treatment of the disease is staggering.   
The development of cancer of the prostate gland is influenced by a milieu of factors, 
including heredity, race, age, diet, physical activity, sexual factors and obesity [3].  Age is an 
important risk factor that affects the likelihood of contracting the disease. As a man ages, his risk 
of developing prostate cancer increases. The incidence of prostate cancer peaks around the age 
of 70 and begins to decline slightly [4].  The mean age of death of a man is approximately 76 
years [4]. Figure 1-1 displays the incidence of prostate cancer per 100,000 patients broken down 
by age, the data for the figure was obtained from the National Cancer Institute Surveillance 
Epidemiology and End Results database.  Another important risk factor that affects the 
development of prostate cancer is the race of the patient. Incidences of prostate cancer are 
significantly higher for an African-American than they are for a white male. African- American 
men have a higher incidence of prostate cancer at every age than their white counterparts [4] .  
The non-age adjusted incidence of prostate cancer for men in the United States  is 268 out of 
every 100,000 men.  
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Figure 1-1: Incidences of prostate cancer vary with the age of the patient 
The incidence of prostate cancer varies with the age of the patient. Cancer of the prostate gland is 
exceedingly rare in men under the age of 50. As a man continues to age, the incidence of prostate 
cancer begins to increase dramatically and peaks at approximately 70 years of age [4].  
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Figure 1-1: Incidences of prostate cancer vary with the age of the patient 
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Caucasian males suffer a lower than average incidence of prostate cancer at a rate of 251 
men diagnosed for every 100,000. African-Americans have a much higher incidence of prostate 
cancer, 385 out of every 100,000 men will suffer from cancer of the prostate gland.  Figure 1-2 
shows the overall incidence of prostate cancer broken down by age and race [4].  
The incidences of prostate cancer have experienced dramatic fluctuations in rates of 
disease diagnosis. The non-age adjusted rate of incidence per 100,000 persons is plotted for each 
year from 1975 – 2006 in Figure 1-3. From 1975 to 1994 the diagnosis of prostate cancer 
increased significantly. This increase in diagnosis of the disease is in part because the average 
life span of Americans has increased and as previously mentioned men suffer from an increased 
risk as they age. Other factors that may have lead to an increased rate of diagnosis are an 
increased awareness of the disease and an increased availability of diagnostic techniques that 
enable physicians to more easily detect the presence of a diseased prostate gland [5]. In 1986, 
the food and drug administration (FDA) approved the use of the prostate specific antigen (PSA) 
test to monitor the progression of cancer. In 1994, the FDA extended the utility of PSA analysis, 
allowing physicians to utilize the level of PSA in the blood as a tool for the diagnosis of prostate 
cancer. Prior to approval of the PSA screening tool, physicians were limited to diagnosing 
prostate disorders by digital rectal examination of the gland.  
Digital examination of the prostate gland is less effective than PSA for detection of 
tumors [6]. In a multi-centered comparison of digital examination to serum levels of prostate 
specific antigen, it was shown that the serum PSA level has a 32% positive predictive value of 
diagnosing cancer of the prostate. While the digital rectal examination, only has a positive 
predictive value of 21%. If the two methods are utilized  
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Figure 1-2: Incidences of prostate cancer vary by age and race 
Cancer of the prostate gland is more common in men around the age of 70 than at any other age. 
For each age group, an African-American male is much more likely to get cancer of the prostate 
than his white counterpart [4].  
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Figure 1-2: Incidences of prostate cancer vary by age and race 
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Figure 1-3: Trends in prostate cancer diagnosis 
In 1975, approximately 600 of every 100,000 men without regard to their age were diagnosed 
with prostate cancer. In the middle part of the 1980’s, the numbers of persons diagnosed with 
prostate cancer began to grow exponentially. It is hypothesized that the increase in diagnosis of 
patients with the disease is a result of an increase in the average life span, an increased awareness 
of the disease, and the advent of the PSA screening tool [6]. Even though it was not officially 
endorsed by the FDA, it is thought that many physicians were using the PSA level as a method to 
screen for potential tumors [5].  
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Figure 1-3: Trends in prostate cancer diagnosis 
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simultaneously, the positive predictive value increases substantially to nearly 78%.  
 
The role of genes in prostate tumorigenesis 
 
Tumors of the prostate gland are highly heterogeneous clinically and histologically[7].  
Despite the heterogeneity of the tumors, it has been noted that several genes may play a role in 
the development of prostate cancer and tumorigenesis.  Highly metastatic androgen independent 
tumors were found to exhibit point mutations in the androgen receptor approximately 50% of the 
time [8].  Testosterone binds to the androgen receptor and stimulates transcription of the 
androgen responsive genes. Genes regulated by this manner cause the cells of the prostate to 
grow.  Androgen independence has long been suspected to play a role in oncogenesis of the 
prostate.  
There are many other genes that are suspected to play a part in tumorigenesis. A recent 
study that attempted to identify a set of biomarkers to diagnose and stage tumors of the prostate 
found several genes to be differentially regulated in prostate cancer [9]. Table 1-1 highlights 
some of the most differentially regulated genes identified. Clearly, many genes are thought to 
play a role in the development of prostate cancer through either point mutations that inactivate 
the gene or through functional dysregulation.  
It was recently discovered that there exist a novel class of small RNA elements that play a 
large role in gene regulation by blocking translation or marking the transcript for degradation 
[10]. These small RNAs are better known as microRNAs (miRNAs, miRs).  
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Table 1-1: Genes predicted to regulate tumorigenesis of the prostate 
 
Genes that are differentially regulated between normal prostate cells and cancerous cells of the 
prostate gland [9]. The function of the genes was inferred by examining the information 
contained in the Information Hyperlinked over Proteins database [11].  The chromosomal 
location of each gene was examined in order to identify potential genes that lie in regions of the 
chromosome with a known loss of heterozygoisty involved in prostate tumorigenesis. 
Chromosomal locations were determined using the Entrez cytogenetic band information from the 
GeneCards resource [12]. Each of the genes listed in this table are suspected to play a role in the 
development or progression of prostate cancer.  
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Table 1-1: Genes predicted to regulate tumorigenesis of the prostate 
Gene 
Symbol 
Gene Name Function Chromosome 
IGFBP-5 Insulin Like Growth 
Factor Binding Protein 5 
Binds to insulin like growth factors 
and modulates cell growth; 
upregulated in metastatic cancer of the 
prostate 
2q33-36[13] 
FAT  FAT Tumor Suppressor 
Homolog 
Cadherin related tumor suppressor 4q35 [13] 
RAB5A RAS related protein 5 B Member of the RAS oncogene family; 
regulates vesicular trafficking 
3p24-22 [13] 
MTA1 Metastasis associated 
protein 1 
Histone deacteylase inhibitor 14q32.3 [13] 
MYBL2 v-myb myeloblastosis viral 
oncogene homolog 
(avian)-like 2   
Transcription factor involved in cell 
cycle progression 
20q13.1 [13] 
HPN Hepsin Cell growth inhibitor 19q11-13.2 
[13] 
PIM1 Pim-1 oncogene Proto-oncogene 
Serine/ threonine protein kinase 
6p21.2 [13] 
14 
 
Discovery of microRNA and their role in development and disease 
 
MicroRNA molecules are short, endogenous molecules that play very important roles in 
gene regulation by modulating protein levels in the cell [14].  It appears that microRNAs bind to 
complementary sequences in the target gene and repress protein translation or mark the protein 
for degradation. First discovered in 1993 in C. elegans as temporal regulators of worm 
development, microRNAs have been found to be ubiquitous in eukaryotes[15]. The Sanger 
microRNA database was created in 2002 with a list of 218 microRNAs obtained from direct 
submission by researchers [16]. In September 2009, version 14.0 was released with a total of 
10,883 unique microRNA sequences in a variety of organisms. The Sanger microRNA 
repository currently lists 772 human microRNA molecules. It is hypothesized that there are 
many other microRNAs that have yet to be located in the human genome. miRNAs are involved 
in numerous cellular functions and have been shown to be involved in many critical and diverse 
cellular processes from cellular differentiation, viral defense, and regulation of cellular signaling 
networks [17]. Researchers have just begun to unravel the functions of a few microRNA 
molecules in everyday cellular processes and disease progression. There remain a large number 
of miRs that have yet to be explored.  
Mature microRNAs are approximately twenty two nucleotides in length and are thought 
to bind to the 3’ untranslated region of the messenger RNA and guide the RNA induced 
silencing complex to the message. After the microRNA binds to the mRNA, the mRNA is 
translationally repressed or degraded [16].  Elucidating the exact role of microRNA regulation 
and dysfunction in disease continues to be a complicated undertaking.  
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microRNA role in cancer progression 
 
microRNA molecules play a role in the development of several forms of human cancer 
including breast, prostate, lung, thyroid, and B cell lymphoma [18].  Several microRNAs 
regulate critical biological processes such as cell proliferation control, cell hypertrophy, 
apoptosis, cell survival and insulin secretion [19]. As cancer is the end result of uncontrolled 
proliferation and survival of damaged cells, these biological functions have previously been 
shown to contribute to the development and progression of cancer.  
MicroRNAs can contribute to oncogenesis by functioning as oncomiRs or tumor 
suppressors. miRs that regulate genes controlling cell proliferation, hypertrophy, and 
angiogenesis are often considered to function as tumor suppressors [20]. Loss or deregulation of 
tumor suppressing microRNAs imparts a growth or survival advantage to the cells, resulting in 
the formation of tumors. miRs that regulate apoptosis are often considered oncomiRs, increased 
levels of oncogenic microRNAs will impart an advantage to the cells and lead to increased 
tumor formation.  
microRNA-17-3p functions as a tumor suppressor in the prostate 
 
microRNA-17-3p has been shown to affect the tumorigencity of the prostate gland [21]. 
An in vitro cancer progression model system of genetically related prostate sublines showed 
increasing or decreasing levels of miR17-3p that negatively correlate with the oncogenic nature 
of the tissue [21]. The parental P69 cell line is a tumorgenic, non-metastatic cell that shows 
relatively high levels of human microRNA-17-3p. The highly metastatic cell line, M12 showed a 
two-fold decrease in the level of microRNA-17-3p. The M12 subline has been shown to contain 
16 
 
a loss of one copy of chromosome 19p-13 that resulted from an unequal translocation of 
chromosome 16:19. The F6 subline is a poorly tumorigenic, non-metastatic cell line that resulted 
from the micro-cell fusion techniques for restoration of the second copy of chromosome 19. The 
F6 subline expresses higher levels of miR17-3p than the parental P69 (Figure 1-4).  Restored 
expression of miR-17-3p in the M12 cell line was shown in vitro and in vivo to reduce 
tumorigencity by at least 50% [22].These experiments clearly show that microRNA-17-3p 
functions as a tumor suppressor in vitro [21].   
Clinical human samples derived from formalin-fixed, paraffin embedded samples 
obtained after prostatectomy confirmed that levels of microRNA-17-3p decrease as 
tumorigencity increases [21].  Relative levels of miR-17-3p were significantly decreased in 
regions of the prostate that were cancerous. Further, it has been shown that levels of miR17-3p 
decrease as the Gleason score of the tumor increases. Essential to understanding the role of the 
microRNA in the tissue is the identification of putative targets of the microRNA. Previous 
studies show that miR17-3p regulates expression of vimentin [22].   
 
Role of intermediate filament proteins in cancer  
 
 Intermediate filaments are fibrous proteins found within the cytoplasm and nucleoplasm 
of most eukaryotic cells [23]. Some intermediate filaments like vimentin tend to be peri-nuclear 
localized and form a cage around nucleus extending to the surface of the cell. It has long been 
known that intermediate filaments are essential for the internal integrity of the cell and the shape 
of the cell. However, it has become clear in the past few years, that intermediate filament 
proteins are dynamic molecules involved in many regulatory functions.   
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Figure 1-4: Genetically related prostate cancer progression cell lines 
Unique genetically related cell line, derived from injection of prostate cancer cells into nude, 
athymic mice [24]. The parental cell line (P69) is a slightly tumorigenic, non-metastatic cancer 
cell line. After several rounds of injection, the cells became highly tumorigenic and metastatic 
(M12). The subline was noted to exhibit an unequal translocation of chromosome 16:19. 
Microcell fusion techniques were used to inject the missing region of chromosome 19 into the 
M12 subline [25]. After insertion of the missing region of chromosome 19, the subline became 
less tumorigenic and non-metastatic (F6).  
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Figure 1-4: Genetically related prostate cancer progression cell lines 
 
Name of cell 
subline 
Description Relative levels 
of vimentin 
Relative levels 
of miR-17-3p 
P69 Parental cell line, tumorigenic and 
non-metastatic 
0.09 0.0032 
M12 Highly tumorigenic and metastatic 
subline; Ch 16:19 translocation 
0.24 0.0018 
F6 Restored chromosome 19; non-
tumorigenic 
0.01 0.0038 
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Vimentin is an intermediate filament protein that is produced by the Vimentin gene on 
chromosome 10p13 [12]. The protein is 466 aminoacids in length and has a mass of 53.6 kDa. 
Vimentin has been shown to be differentially regulated in prostate cancer cell lines. Previous 
studies have demonstrated that tumors containing higher levels of vimentin are more motile and 
invasive [26]. The highly metastatic M12 cell subline has significantly higher levels of vimentin 
compared to the less tumorigenic P69 and F6 cell lines [22]. Likewise, vimentin expression was 
significantly increased in highly invasive, androgen insensitive cell lines (LnCap CL1) [26].  
Subcutaneous injection of tumor cells into nude, athymic, male mice revealed that the 
M12 subline is highly tumorigenic  in vivo [22]. The mice injected with the M12 subline all 
formed tumors within nine to fifteen days. The F6 subline injected mice failed to grow a tumor 
or grew very small tumors 120 days post-injection. As the levels of vimentin vary among the cell 
lines, the effect of vimentin on tumor growth was investigated by injecting mice with M12s  
along with a vimentin small hairpin RNA (shRNA). The mice injected with the M12 variant 
expressing a vimentin shRNA (M12 +siVim). In the mice injected with the M12 + siVim variant 
the size of the tumors was greatly reduced compared to the M12 subline alone. To investigate the 
role of human microRNA17-3p on tumor formation in nude, athymic mice, the animals were 
injected with an M12 variant subline containing a microRNA-17-3p over expression vector [21]. 
Tumor formation was reduced but not to the same degree as the mice containing tumors with the 
shRNA for vimentin. It seems that miR-17-3p may regulate some protein(s) that infers a slight 
advantage to the cells. In order to further understand the role of miR-17-3p in the prostate, one 
must identify these other putative targets of the miR, in addition to vimentin. 
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Biogenesis of microRNA molecules 
 
Essential to understanding the role miRNAs play in cellular processes is the identification 
of their putative targets. The past decade has seen a large increase in the numbers of 
computational methods for the identification of miR/ gene targets. The methods employed by the 
various computational tools are diverse. They range from simple string based methods to more 
complicated markov models. Before understanding the techniques of microRNA target 
prediction, one must understand the biogenesis of microRNA and the types of interactions 
between miRNAs and their target genes.  
miRNA genes can be part of a polycistronic transcript of 2- 7 microRNA genes under the 
control of a common transcriptional regulator or can be excised from introns of protein coding 
genes [27]. MicroRNAs in animals are created using a two step process [28].  Figure 1-5 
illustrates the step wise biogenesis of the microRNA molecule. The first step involves 
transcription of a several hundered nucleotide in length transcript that is called the pri-miRNA 
by RNA pol II or RNA pol III. The pri-miRNA is processed into a smaller structure of 
approximately 70 nucleotides (pre-miRNA) in length while in the nucleus. The processing is 
accomplished by a complex of several proteins, the most important being Drosha [29]. The pre-
miRNA has a characteristic stem loop shape and is exported from the nucleus by a complex of 
Exportin 5 of Ran-GTP [30]. Once in the cytoplasm, the pre-miRNA undergoes the second 
phase of processing, where it is processed by the enzyme Dicer into its mature form that is 22 
nucleotides in length [31].  
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Figure 1-5: Biogenesis of microRNA 
 
1. MicroRNA molecules are transcribed from introns of protein coding genes or are a part of 
a polycistronic transcript by RNA polymerase II or RNA polymerase III. The pri-miRNA 
is several hundred nucleotides in length and contains regions of stems and loops. [27] 
2. A complex of enzymes that includes Drosha, a Rnase II enzyme, cleaves the pri-miRNA 
into the shorter microRNA molecule (pre-miRNA) [27, 32]. 
3. The pre-miRNA has a characteristic stem loop shape and is approximately 70 nucleotides 
in length [32].  
4. The pre-miRNA is exported from the nucleus to the cytoplasm by the Exportin V 
complex [30]. 
5. In the cytoplasm, the enzyme Dicer recognizes the characteristic stem loop shape of the 
pre-miRNA and cleaves into the functional mature microRNA molecule [31].  
6. Mature microRNAs can be generated from either the 5’ or the 3’ end of the stem loop of 
the pre-miRNA [29].  The mature micrRNA is typically 22-25 nucleotides in length and 
binds to the 3’ untranslated region of the mRNA transcript.  
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Figure 1-5: Biogenesis of microRNA 
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Computational methods of identification of putative targets 
 
MicroRNAs interact with their targets through sequence complementarity. In some cases, 
seven complementary bases on the 5’ end of the microRNA are adequate to post-
transcriptionally regulate protein levels [33]. Bases 2-7 of the microRNA seem to be critical in 
order for the microRNA to be able to bind to its target. These bases are commonly referred to as 
the seed region of the miRNA. Many miRNA/ target interactions exhibit 3’ compensatory loop 
interactions that further stabilize the structure of the molecule. Due to the relatively short size of 
microRNA molecules and the small number of complementary bases, computational prediction 
of potential targets of miRNAs is very difficult [34]. Other features that complicate attempts at 
computational prediction of interactions are the presence of regions of mismatches between the 
microRNA and the target 3’ UTR, G:U wobbles and sequence bulges [35]. Table 1-2 lists the 
details of some of the most commonly utilized tools for prediction of microRNA targets.  
 
The miRanda algorithm 
 
One of the earliest attempts to identify potential putative targets of microRNAs was the 
development of the miRanda algorithm [36]. The algorithm employed by miRanda utilizes a two 
step process. First, it inputs the sequence of the microRNA and compares it to the 3’ untranslated 
region of all genes in the input file. Seed region base complementarity is given a higher reward 
than complementarity of bases on the 3’ end of the microRNA molecule. The reason for this 
reward is because it is generally thought that the seed region interactions are critical to the 
ability of a miRNA to repress protein translation. The program evaluates each potential match 
based on base sequence complementarity. Complementary sequences that exceed a pre-defined  
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Table 1-2: Common MicroRNA/ Target Prediction Tools 
Computational methods to identify potential putative targets of microRNA are essential to 
elucidation of their role in the biological realm. We list some of the most commonly cited 
computational tools in existence, the world wide web address of each tool and the number of 
times each prediction tool has been cited in microRNA related literature as of September 2009. 
Often the number of citations is used to indicate popularity of a program. Utilizing this metric, it 
appears that PicTar and TargetScan are the most commonly utilized tools for microRNA target 
identification. 
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Table 1-2: Common MicroRNA/ Target Prediction Tools 
Tool Web Location  Type of Tool 
Times 
Cited Reference 
Diana  
MicroT 3.0 http://diana.cslab.ece.ntua.gr/microT/  Precompiled List  
Not 
Available  [18] 
Miranda http://www.microrna.org/microrna/home.do  
Open source and 
precompiled list 30 [36] 
PicTar http://pictar.med-berlin.de/  Precompiled List  595 [37] 
TargetScan  http://www.targetscan.org/  
Open source and 
precompiled list 1081 [38] 
RNA 22 http://cbcsrv.watson.ibm.com/rna22.html  
Precompiled List 
and webserver 114 [39] 
 
.  
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threshold set by the user will enter the second phase of evaluation. Potential matches will be 
evaluated for thermodynamic stability using the RNAlib module of the Vienna RNA package 
[40].  
 
TargetScan 
 
TargetScan employs an algorithm that scans the 3’ UTR of possible targets for the 
presence of one of three types of canonical seed region interactions [38]. The most favorable and 
highly scored interaction results from complementarity of positions 2-8 of the microRNA and 
the presence of an adenine nucleotide at the far 3’ end of the potential binding site in the UTR. 
The second most favorable interactions come from binding of bases 2-7 of the microRNA, along 
with an adenine residue at the end of the bound region of the target or binding of bases 2-8 of 
the microRNA to the target. The least favorable target considered to be possible utilizing the 
TargetScan algorithm is complementarity of bases 2-7 of the microRNA and target UTR.  
 
PicTar 
 
PicTar is a computational tool for the prediction of microRNA targets that not only 
employs seed region interactions, but also ensures evolutionary conservation and secondary 
structure stability [37].  PicTar accepts as input two files; the first contains a multiple sequence 
alignment of the 3’ UTR of related species and a second file containing the microRNA 
sequences of the researcher. The algorithm employed by PicTar searches the multiple sequence 
alignment for sequences that would adhere to the seed region by strictly following the Watson-
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Crick base pairing rules. The algorithm allows the seven bases of the seed region to begin at 
either position one or two of the microRNA. Potential microRNA binding sites are filtered by 
free energy of heteroduplex formation. Binding sites that have a free energy lower than the 
desired threshold are retained and further analyzed. If the potential binding site exists in a region 
that is completely conserved across several species, the binding site is considered to be valid and 
a hidden markov model maximum likelihood fit score is calculated. Potential binding sites are 
ranked based on their score. Higher scores represent binding sites that are more likely.  
 
Diana MicroT 3.0 
 
Diana microT 3.0 utilizes sequence similarity, free energy of heteroduplex formation and 
to a lesser degree multiple species conservation to identify potential binding sites [18]. The 
algorithm employed by Diana, pulls out the first nine nucleotides (driver sequence) and uses a 
sliding window approach to scan the 3’ UTR of the gene for sequences that are complementary 
to the driver sequence in at least six consecutive nucleotides. The program allows a single G:U 
wobble, as long as there are at least six Watson-Crick base pairs in the alignment.   
Potential binding sites with less than seven Watson- Crick pairs are further evaluated 
using the free energy value of heteroduplex formation using the RNA hybrid algorithm [41]. The 
first step of filtration is accomplished by passing the actual microRNA sequence and the 
potential binding site to the RNA hybrid program. Following the calculation of the actual binding 
energy, a hypothetical binding energy is calculated by estimating the binding energy of the 
perfectly complemented sequence to the microRNA. If the ratio of theoretical to hypothetical 
binding energies is greater than 0.74, the sequence is identified as a potential “miRNA 
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recognition element (MRE)” or a predicted binding site [18].  
Sequences of multiple species are examined to determine if the potential MRE is present 
in other species to identify sequences that are conserved in multiple species [18]. It is 
hypothesized that sequences that have been conserved though out millions of years of evolution 
possess functional significance. Species that are examined include humans, rats, mice, dogs and 
zebrafish. A conservation score is generated that is equal to the number of species that contain 
the individual MRE. The conservation score and the binding score are combined into a 
microRNA target gene score (miTG). Potential binding sites are ranked by their miTG scores. 
 
RNA22 
 
RNA22 is a pattern based method that relies on information inherent in the nucleotide 
sequences of the microRNA molecule [39]. RNA22 uses the Teiresias algorithm to identify 
patterns in the sequences of microRNA molecules from reference species in the RFAM database 
[42, 43]. Following pattern identification, the UTRs of the genes of interest are scanned for the 
presence of “target islands” that possess at least one of the patterns identified in the pattern 
matching step of the algorithm. Target islands are matched to candidate microRNA molecules 
based on sequence complementarity. A score, based on the number of Watson-Crick base pairs in 
the heteroduplex, is generated. Potential binding sites that exceed a given threshold are returned 
to the user.  
Project Objectives 
The computational identification of putative targets of microRNA is critical to 
understanding the role a given miR plays in development and disease. Presumably, programs that 
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include multiple features of miR/ target interactions will be more accurate than programs that 
include fewer features. In practical terms, accuracy is defined as the ability of a method to 
identify true interactions and reduce the number of false predictions. Researchers desire to 
identify the greatest number of true interactions at the lowest cost of investigation in terms of 
fiscal cost and manpower. With so many computational methods in existence, researchers must 
understand the features, advantages, and benefits of each of the programs.  
In order to fully understand the mechanism of tumorigenesis, this project seeks to identify 
putative targets of miR-17-3p using a combination of computational and traditional wet-lab 
techniques. Prior to the utilization of previously published microRNA prediction tools, all tools 
were evaluated using a standardized set of proven microRNA and gene targets to measure the 
accuracy of the programs. As part of this project, we designed and implemented a comprehensive 
microRNA annotation and prediction interface (MAPI) that increased the accuracy of current 
programs. MAPI was utilized to identify potential targets of miR-17-3p that are expressed in the 
prostate gland and involved in tumorigenesis. Utilizing wet-lab techniques, the targets were 
evaluated in a cancer cell progression model using western blot analysis of target protein levels. 
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Specific Project Aims 
 
 Evaluate current computational microRNA prediction tools to determine which program or 
combination of programs offer users the best balance of sensitivity and specificity. 
 Design and implement a comprehensive computational interface that increases the 
effectiveness of previously published programs by filtering irrelevant targets 
o Include transcriptional profiles for various tissues and disease states 
 Use the computational interface to identify potential targets of human microRNA-17-3p that 
potentially impart an oncogenic advantage to the cells when overexpressed. 
 Utilizing a cancer cell progression model, verify that the levels of the predicted target of 
microRNA-17-3p are more abundant in the highly tumorigenic and metastatic M12 cell line. 
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Chapter 2 
Evaluation of computational methods of microRNA target identification 
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Methodology to compare microRNA prediction programs 
  
  The past decade has seen a large increase in the attempt to determine the exact 
role microRNAs play in the maintenance of health and the development of disease. To 
understand the role of a given microRNA in human disease, a researcher must first identify its 
putatitive targets. Many computational tools/ programs have been developed to assist 
researchers in the prediction of microRNA target gene interactions. The methods employed by 
the various computational programs vary greatly. This project seeks to evaluate the sensitivity of 
each method along with determining the total number of predictions. This work compares the 
predicted targets of Diana MicroT, Miranda, Pictar, TargetScan, and RNA22 utilizing a set of 
microRNA molecules that are shared by all methods [18, 37-39, 44].  This work only evaluates 
the performance of the various programs to predict human microRNA gene interactions as most 
researchers are interested in determining the role microRNA play in the development of human 
disease.  
 A previous study conducted by Sethupathy, Megraw, and Hatzigeorgiou in 2006 
evaluated the sensitivity of various target identification programs using a benchmarking dataset 
of targets from the Tarbase database for experimentally proven microRNA gene target pairs [45, 
46]. At the time of that publication, there were only 84 such targets for 32 microRNAs that had 
been proven. In the past three years, both the number of putative targets for microRNAs and the 
number of prediction programs have increased dramatically. It is reasonable to suspect that with 
the increase of available data and more advanced methods that the former conclusions are no 
longer valid.  
Researchers found that the single best tool in existence in 2006 was Miranda and that the 
best sensitivity could be achieved by overlapping the predictions from every program available 
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[45]. However, biologists cannot search through the number of predictions generated by 
overlapping the predicted targets. Scientists often attempt to enrich the number of true 
interactions by considering only microRNA targets that have been predicted by more than one 
method. The previous study recommended that in order to balance the needs of researchers to 
maintain a high level of sensitivity and allow researchers to search through a lower number of 
potential targets, only targets  predicted by PicTar and TargetScanS  be considered [37, 38].  
 
Compilation of Predictions 
 
 Predictions for DIANA-MicroT 3.0 were downloaded in a pre-compiled tab delimited 
text file from their webserver, which can be found at the URL listed in Table 1. Human 
microRNAs that target a unique gene with a miTG score of at least 1.0 were included in our set 
of predicted targets. Multiple interactions per gene, if possible, were collapsed into a single 
predicted pairing. PicTar predictions were compiled using a PERL script that downloaded all 
predicted targets for each human microRNA that was available on the PicTar server as of July 5, 
2009.  TargetScan 5.1 human data was downloaded from the TargetScan server using the 
predicted conserved targets file. Precompiled predictions were downloaded from Miranda using 
the web address specified in table 1 and downloading the human miRNA target site predictions 
file. RNA 22 predictions were assembled using the precompiled data file for only the 3’-UTR 
region.  
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Development of a standardized microRNA/ target comparison set 
 
 In order to measure the sensitivity of each computational program, we assembled a set of 
microRNA/ target interactions that have been experimentally proven. Tarbase and miRecords are 
web based resources where researchers report  microRNA/ gene pairs that have been 
experimentally validated [46, 47]. By combining the two datasets and eliminating multiple 
entries, we developed a comprehensive list of proven human microRNA/ gene interactions. 
MicroRNAs have been shown to bind to more than one site on a given target gene, in this study 
we eliminated such multiple binding sites and considered the pairing as a single predicted 
interaction. We compiled a list of 826 experimentally verified microRNA targets.  
 
Sensitivity Analysis 
 
As the number of microRNAs vary slightly between tools, it was necessary to create a 
standard set of microRNA molecules that could be used to accurately compare each tool. We 
intersected the microRNA identifiers from each tool and found that only 139 microRNAs were 
shared among all of the tools that we compared in this study. Of these 139 common microRNAs, 
we found that there were 451 unique interactions. These interactions were the only predictions 
that we utilized in the sensitivity analysis.  
Each prediction method previously described was compared to the standardized 
comparison target set in order to determine how well each tool performed. Of particular interest 
to microRNA researchers is the sensitivity of each tool. Figure 2-1 shows the formula for 
derivation of sensitivity. Sensitivity evaluates the proportion of experimentally proven 
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interactions that are correctly identified by the evaluated program. Successful tools will ideally 
be able to correctly identify a majority of the experimentally verified microRNA targets. 
Following individual program analysis, we evaluated various combinations of tools to 
determine if there exists an ideal combination of computational tools that can identify most 
microRNA targets. In order to accomplish this objective, each set of microRNA/ target 
predictions was pair wise intersected with all other tools in an effort to determine the 
sensitivities of each possible combination of tools. Likewise, sets of predictions for each tool 
were overlapped (unioned) in pair wise fashion with every other tool in an attempt to increase 
the sensitivity. We illustrate the concept of mathematical union and intersection in Figure 2-2.  
Many researchers base their decision on which microRNA tool to use based solely on the 
sensitivity of the various tools. However, one could theoretically predict every gene to be a 
target of each microRNA and achieve a sensitivity of 100%. Specificity measures the proportion 
of incorrect or negative interactions that are correctly identified. It is difficult to measure the 
specificity of a microRNA target prediction tool, as there is not a comprehensive database that  
tracks negative experimental results. Therefore, as a surrogate for specificity, in this study we 
compared the performance of each tool by calculating the total number of predictions.  The 
numbers of predictions are only the predicted pairings that originate from our set of 139 
common microRNA molecules.  
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Figure 2-1: Sensitivity Analysis 
 
Details the analysis process utilized to measure sensitivity of each microRNA prediction tool 
and combination of prediction tools.  
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Figure 2-1:  Sensitivity Analysis 
 
Sensitivity is defined as: 
 
Number of true positive interactions
(Number of true positive interactions + number of false negative interactions)
 
 
True Positive Interaction 
 
Interaction predicted by the tool or combination of 
tools and is found to be in our standardized list of 
experimentally proven targets 
False Negative Interaction A member of the standardized list of experimentally 
proven interactions that is not correctly predicted by 
the tool or combination of tools.  
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Figure 2-2: Venn diagram of the union and intersection of the PicTar and Diana MicroT 3.0 
datasets 
 
 
Targets were predicted for the 139 microRNAs common to all tools. Diana MicroT 3.0 predicts 
approximately 373,000 total interactions among our standardized list of microRNAs. PicTar 
predicts slightly less than 49,000 interactions among the 139 microRNAs in common to all 
prediction programs compared. If a researcher only considers the microRNA targets predicted by 
both programs (targets in the intersection of the two tools), the number of potential targets is 
reduced to approximately 29,000 possible targets. Sensitivity is increased by taking the union of 
the two sets of predicted targets. The union of the datasets includes any targeted predicted by 
either Diana MicroT3.0 or PicTar. The union of the two datasets predicts nearly 383,000 possible 
targets.  
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Figure 2-2: Venn diagram of the union and intersection of the PicTar and Diana MicroT 3.0 
datasets 
Diana 
MicroT 
3.0 PicTar
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Findings 
 
 There exist many computational methods for prediction of microRNA/ gene interactions 
in humans. In this study, we compared five commonly used microRNA prediction tools.  A list 
of tools compared in this study, along with the web location, method of data acquisition, and the 
number of citations referencing that tool are listed in Table 1-1.  
In Table 2-1, we show the sensitivity and the number of total predictions generated using 
our list of common microRNAs for each tool and combination of tools. This analysis found that 
the single best performing microRNA/ gene prediction tool is DIANA-MicroT 3.0 [18]. 
Although this program has been around for several years, version 3.0 was first described in July 
2009 and was included in this analysis because of their self reported 66% precision rate. Figure 
2-3 plots the calculated sensitivity versus the total number of predictions for each of the tools. 
The algorithm utilized by DIANA-MicroT 3.0 considers several types of seed region binding, 
cross species conservation, and thermodynamic stability of seed region interactions. Potential 
binding sites are given a microRNA target gene score (miTG) which reflects the relative strength 
of the prediction. Our analysis found that DIANA-MicroT 3.0 was able to achieve a sensitivity 
rating of nearly 46%. However, to accomplish this level of sensitivity, the program predicted 
over 370,000 microRNA/ gene pairings. Users can decrease the total number of predictions by 
increasing the minimum miTG score. 
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Table 2-1: Sensitivity Analysis of each Prediction Tool and Combination of Prediction Tools 
 
 
Comparison of the sensitivity and total number of predictions for each microRNA target 
prediction tool and combinations of the intersections and unions of various tools. Using this 
analysis it is clear that to achieve the best sensitivity, a researcher needs to combine all of the 
predictions of as many tools as possible. However, in order to achieve that level of precision, a 
researcher will need to look through nearly 3800 predictions per microRNA. The single best tool 
is Diana MicroT 3.0 which achieves a sensitivity of nearly 46% while predicting less than 2800 
possible interactions per microRNA [18, 37-39, 44]. Programs that achieve the highest 
sensitivity are able to more correctly identify true interactions.  
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Table 2-1: Sensitivity Analysis of each Prediction Tool and Combination of Prediction Tools 
Tool Sensitivity 
Total 
number of 
predictions 
Diana 45.9 372530 
Miranda 4.2 14612 
PicTar 24.4 48948 
RNA22 10.8 85481 
Target Scan 21.4 209151 
Intersections of tools 
 
  
Target Scan/ Miranda Intersection 2.9 4327 
Diana/ PicTar Intersection 18.3 28617 
Miranda/ TargetScan Intersection 2.2 3283 
Diana/ Miranda Intersection 8.3 30080 
Miranda/ PicTar Intersection 1.7 843 
Diana/ TargetScan Intersection 17.1 131114 
RNA22 / TargetScan Intersection 2.5 13659 
PicTar/ TargetScan Intersection 9.7 14068 
Miranda/ RNA22 Intersection 1 1089 
PicTar/ RNA22 Intersection 4.7 4800 
Unions of tools 
 
  
Diana/ Miranda Union 47.3 382815 
Diana/ PicTar Union 52 392861 
Miranda/ TargetScan Union 23.4 220480 
Diana/ RNA22 Union 48.5 427931 
Miranda/ PicTar Union 26.9 62717 
Diana/ TargetScan Union 50.2 450567 
RNA22/ TargetScan Union 29.7 280973 
PictTar/ TargetScan Union 36.1 244031 
Miranda/ RNA22 Union 14.1 99004 
PicTar/ RNA22 Union 30.5 129629 
Union of all tools 56.9 528237 
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Figure 2-3: Scatterplot Comparison of MicroRNA Prediction Tools 
 
The sensitivity versus the total number of predictions for individual tools and the combinations 
of Pictar and Diana MicroT 3.0 was plotted [14, 37-39, 47]. Our analysis proves that the best 
method to identify the greatest number of experimentally proven targets is to consider any target 
predicted by any microRNA target prediction tool. However, using this approach researchers 
will have to search through an average of 3600 targets per microRNA. This is a daunting task 
that can only be accomplished by a large research group with abundant financial resources.  
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Figure 2-3: Scatterplot Comparison of MicroRNA Prediction Tools 
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 The sensitivity of predictions of DIANA-MicroT 3.0 can be increased by adding the 
predictions of any other tool to the predictions made by DIANA. The union of PicTar and 
DIANA together are able to achieve over 50% sensitivity [18, 37]. Due to significant overlap of 
the predicted targets in these two datasets, this increased sensitivity can be accomplished with 
only a five percent increase in the total number of predictions. The best sensitivity can be 
achieved by compiling all of the predicted targets of each of the target prediction programs into 
a single list. This results in a near 57% sensitivity value, but the total number of predictions 
would be over a half million or nearly 3600 targets per microRNA molecule. It does not make 
biological sense that a single microRNA would target over one tenth of the human genome. 
Previous groups have suggested that it is more biologically plausible to suspect that each 
microRNA may target nearly 500 genes [12]. 
   PicTar searches a multiple sequence alignment of RNA sequences for perfect seed 
region binding of the first seven nucleotides beginning at position 1 or 2 of the 5’ end of the 
mature microRNA sequence [37]. The PicTar algorithm filters out potential targets that do not 
meet a minimal free energy cutoff using the RNA Hybrid program [48]. In addition to seed 
region binding and thermodynamic stability, PicTar filters out potential false positive predictions 
by ensuring that the UTR sequence is conserved across multiple vertebrate species. According to 
our analysis, PicTar is able to achieve a sensitivity score of nearly 25%.  The number of 
potential targets predicted by PicTar is far less than the number of targets predicted by other 
methods.  Presumably, this would make PicTar one of the more specific programs available for 
use by microRNA researchers.  
 As previously mentioned, biomedical researchers often intersect the predicted targets of 
multiple programs in an attempt to enrich the number of true interactions in their data set. 
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Recently, the validity of this approach was questioned [49]. Our analysis finds that the 
sensitivity of the methods is greatly decreased by intersecting combinations of predicted targets. 
Diana MicroT and Pictar were able to achieve 52% sensitivity when the sets of data were 
overlapped and unioned together. When the list of potential targets was intersected, and only 
targets predicted by both methods were considered, the sensitivity was reduced to 18%.  
 This analysis demonstrates the complexity associated with predicting microRNA targets. 
Researchers seeking to study the effects of a given microRNA on development or disease face a 
difficult task. Currently, the single best tool can only identify approximately half of the 
experimentally proven interactions. This finding highlights the necessity to develop newer, more 
accurate methods of target identification or develop methods that reduce the number of 
predictions associated with overlapping multiple tools. 
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Chapter 3 
Development of the MicroRNA Annotation and Prediction Interface 
(MAPI)
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Features of MAPI 
 
 Cancer is a highly, heterozygous disease resulting from a combination of genetic and 
epigenetic factors. Even though cancers are highly individual, it has been known for quite some 
time that each cancer has a unique molecular signature or molecular portrait [50]. This portrait of 
each cancer profiles the highly variable nature of gene expression as measured by the DNA 
microarray. Recent work has shown that expression profiles of microRNAs are also highly 
variable in various forms of human cancer [51]. miRNA expression profiles can be used to detect 
developmental lineages and differentiate between various stages of the disease. As microRNAs 
regulate gene translation, there exist tissue specific differences among genetic profiles in various 
tissues/ diseases and there exist tissue specific differences among microRNA expression levels. 
Thus, it is reasonable to assume that one could integrate these sources of information and yield a 
more accurate computational method for the prediction of targets of microRNA.  
The microRNA annotation and prediction interface (MAPI) is a comprehensive tool that 
integrates multiple information sources into a single easy to use interface. MAPI was built using 
the MySQL open source database, PERL, and an html front end user interface and provides a 
centralized resource that includes several of the most highly referenced computational prediction 
programs. The database allows end users the flexibility to choose from any of the computational 
tools included in the program or choose from one of several combinations of programs that offer 
the user the highest sensitivity and specificity.  
The greatest strength of MAPI is the ability to filter predicted targets based on numerous 
biological parameters, allowing users to retain a high level of sensitivity and decrease the overall 
number of predictions per microRNA. MAPI allows users to select a tissue of interest and search 
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for targets of a specific microRNA or search for a microRNA(s) that target a gene of interest. 
The program searches for microRNAs and gene targets that are co-expressed in the tissue of 
interest.   
 
MicroRNA annotation 
 
 All microRNA sequences were downloaded from  miRBase. miRBase is a searchable, 
annotated database of microRNA resources [16]. miRBase version 14.0 was used for compilation 
of microRNA attributes. Data was downloaded using the FTP site of the resource at 
ftp://mirbase.org/pub/mirbase/CURRENT/. The files downloaded included the file containing the 
precursor microRNA ID and sequence named hairpin.fa.gz, the file containing the mature 
microRNA ID and sequence named mature.fa.gz, and the file that contained the alternative 
microRNA from the 3’ end of the precursor named maturestar.fa.gz. All files were decompressed 
using the unix operating system and a PERL script was written to extract the name and sequence 
of each human microRNA . Hairpin microRNA molecules were mapped to a chromosomal 
location using the hsa.gff file found in the genomes directory of the above ftp site. Each 
microRNA precursor was linked to the appropriate mature microRNA molecule(s). In some 
cases, a single precursor can give rise to two mature microRNAs. All files were assembled into 
database tables and uploaded to the MAPI interface (Table 3-1 and 3-2).  
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Table 3-1:  Description of precursor microRNA table 
The pre-miRNA table contains a list of all human precursor microRNA molecules. Information 
was obtained from the Sanger microRNA repository. Each pre-miRNA is annotated to include 
the chromosomal location of the precursor molecule, sequence and direction of the molecule in 
reference to the chromosome [16]. 
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Table 3-1: Description of precursor microRNA table 
Precursor  microRNA Table 
microRNA precursor ID 
microRNA accession ID 
Sequence 
Chromosome 
Chromosomal Start 
Chromosomal End 
Length of pre-miRNA 
Chromosomal direction 
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Table 3-2: Description of the Mature microRNA table 
The mature microRNA table contains a list of all human mature microRNA molecules, their 
corresponding sequence, the identifier of the associated the pre-miRNA, and the chromosome 
that gives rise to the mature miRNA.  
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Table 3-2: Description of the Mature microRNA Table 
Mature microRNA Table 
microRNA mature ID 
microRNA precursor ID mapped to mature ID 
Sequence 
Chromosome 
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Table 3-3: Predicted targets of microRNA molecules 
Each predicted interaction of a microRNA and gene are listed in the predicted targets table. The 
computational tool and score generated by that method are listed in the interaction table.  
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Table 3-3: Predicted targets of microRNA molecules 
Predicted Targets of microRNA 
microRNA mature ID 
Target gene 
Interaction score 
Prediction tool  
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Assembly of predicted targets 
 
 Potential targets were assembled for Pictar, TargetScan, RNA22, Miranda, and Diana  
MicroT 3.0 [18, 36-38, 44]. The methodology described in Chapter 2 was used to compile all of 
the predicted targets for each prediction tool. When applicable, multiple interactions of a 
microRNA to a single gene were combined into a single interaction. A singleMySQL table was 
created from the compilation of all predicted interactions (Table 3-3).  
 
Compilation of oncogenic genes 
 
 It is well known that aberrant expression of certain genes imparts an oncogenic nature to 
the cells/tissues. Through the efforts of the National Cancer Institute’s Cancer Genome Atlas, 
many of the genes that have been proven to be involved in tumorigenesis  
have been compiled into a single resource [52] . The Cancer Genome Atlas has assembled a list 
of 386 genes that impart tumorigenicity to the tissue. A privately funded group compiled a list of 
putative oncogenes, tumor suppressors and proto-oncogenes by using literature mining methods 
and called the resource the Cancer Genetics Web. The two resources were combined into single 
comprehensive list using a PERL script that eliminated redundancy of genes. The final list of 
potential cancer causing genes was uploaded into the MAPI resource using MySQL (Table 3-4).  
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Table 3-4: Genes involved in the progression of cancer 
All genes shown to function as oncogenes, proto-oncogenes and tumor suppressors are listed in 
the cancer related genes table. The cytogenetic band of each cancer related gene is listed with its 
corresponding refseq ID.  
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Table 3-4: Genes involved in the progression of cancer 
Cancer related genes 
Alias 
Gene symbol 
Cytogenetic band 
Refseq ID 
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Transcriptional regulation of genes 
 
The National Center for Biotechnology Information hosts the Unigene database [53]. 
Unigene is a centralized, non-redundant database that organizes expressed sequence tags into 
gene oriented clusters. The Unigene database was downloaded from the FTP server at 
ftp://ftp.ncbi.nih.gov/repository/UniGene/. Human transcripts were extracted from the database 
using a PERL script.  
There are over 120,000 unique transcripts expressed by the human genome.  Unigene  
organizes the transcriptional information into the body site that expresses the EST, disease state, 
expression level of the transcript, and the developmental state. The unigene database lists each 
unique transcript and the number of times that transcript has been seen in that particular state. For 
the MAPI interface, the expression level of each transcript was transformed to represent the 
number of transcripts per one million. (Table 3-5).   
 Tissues accomplish their functional goals by regulated expression of necessary 
gene products. Each tissue expresses a unique number and combination of genes. For this study, 
we compared the number of unique transcripts between the normal prostate gland and the 
cancerous prostate gland (Figure 3-1). When the prostate gland becomes cancerous, the number 
of expressed gene products is significantly decreased. In addition to a decrease in number of the 
genes expressed, the average level of expression of each gene increases as compared to the 
normal gland (Table 3-6).  
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Table 3-5: Tissue Specific Gene expression levels 
Each unique unigene transcript is listed, along with the developmental stage/ health state 
associated with each transcript and a normalized level of transcription.  
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Table 3-5: Tissue Specific Gene expression levels 
Gene Expression Table 
Gene ID in unigene format 
Type of transcription 
Tissue 
Expression level in transcripts per million 
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Table 3-6: Comparison of gene expression in the normal and cancerous prostate gland 
Utilizing data obtained from Unigene, we determined that the number of unique RNA transcripts 
decreases in the cancerous prostate gland, as compared to the normal prostate. The tumorigenic 
tissue expresses approximately 30% fewer genes than the non-cancerous tissues. Even though 
the overall number of unique transcripts is fewer, the transcriptional level of each transcript is 
higher in the cancerous tissue than the non-cancerous tissue. At least in the prostate gland, when 
the gland becomes cancerous there is a significant increase in the expression level of a smaller 
number of genes.  
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Table 3-6: Comparison of gene expression in the normal and cancerous prostate gland 
 
Condition Number of 
transcripts 
Average 
expression 
Minimum 
expression 
Maximum 
expression 
Cancer 14505 68.94 9.6 8040.8 
Normal 22087 45.26 5.2 5974.8 
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Figure 3-1: Unique transcripts in the normal and cancerous prostate gland 
The number of unique transcripts in the normal and cancerous prostate gland were extracted and 
compared to one another. The normal prostate gland expresses approximately 23,000 unique 
mRNA transcripts. When the gland becomes cancerous, the number of unique transcripts 
decreases to approximately 15,000. The prostate expresses approximately 15% of the total 
number of possible transcripts in the human genome. 
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Figure 3-1: Unique transcripts in the normal and cancerous prostate gland  
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Genes of the human genome 
 
 
Human genes were extracted from a collection of chromosomal files contained in the 
Genbank resource at NCBI [54]. Genbank is a non-redundant collection of nucleotide sequences 
submitted by researchers in the biomedical field. Even though the resource is maintained by the US 
National Institute of Health, the database is synchronized daily with the European Molecular 
Biology Laboratory (EMBL) nucleotide sequence database and the DNA Databank of Japan. 
Genbank provides a comprehensive collection of all known genetic sequences. The database was 
downloaded on March 2, 2008 from  
ftp://ftp.ncbi.nih.gov/genbank/genomes/Eukaryotes/vertebrates_mammals/Homo_sapiens/GRCh37. 
A PERL script was written to parse desired information from the flat format sequence file. The 
information extracted from Genbank was used to create the genes table of the MAPI interface 
(Table 3-7). 
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Table 3-7: MAPI Human Genes Table 
 
The genes table in the MAPI interface contains the reference sequence ID (Refseq), the gene 
symbol, chromosome of the gene, start and end of the gene and a short description of the role of 
the gene in the cell for all known human genes.  
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Table 3-7: MAPI Human Genes Table 
 
Genes 
Refseq ID 
Contig ID 
Chromosome 
Chromosomal start 
Chromosomal end 
Direction 
Gene symbol 
Description 
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Tissue Specific MicroRNA Prediction 
 
 The potential benefit of tissue co-expression of microRNAs and their targets was 
evaluated, the predictions of Diana Micro T 3.0 and Pictar were overlapped and a set of targets 
from the union was generated. The list of predictions was compared to a list of genes that were 
expressed in the prostate gland. This combination of prediction tools was chosen because the 
union of the two datasets was proven to have the highest level of sensitivity.  The tissue specific 
predicted target list was labeled as the MAPI dataset.   If consideration is not given to tissue co-
expression, the unioned dataset was shown to offer users a near 52% sensitivity but the number 
of predicted targets neared 400,000 (Table 2-1).  
A plot similar to the plot in Figure 2-3 was created and amended to plot the sensitivity of 
each prediction tool against the average number of predicted targets per microRNA molecule. In 
order to measure the sensitivity of tissue specific target prediction, a subset of proven 
interactions that show an expression level of at least 1 transcript per million in the prostate gland 
was assembled and used as a comparison set. The methodology is similar to that described in 
chapter 2. MicroRNA prediction tools were evaluated using the standardized set of prostate 
specific interaction pairs. The sensitivity of nearly every prediction tool was increased with the 
exception of Miranda because proven interactions that are not expressed in the prostate were 
excluded from the comparison set (Figure 3-3).  The sensitivity of Miranda actually decreased 
slightly when considering tissue specificity. The MAPI dataset, assembled from the union of 
PicTar and Diana MicroT 3.0 had an increased sensitivity and a lower number of predictions.  
It appears that including tissue specification increases the sensitivity of prediction 
algorithms and concurrently increases specificity. The benefit to microRNA researchers is that 
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Figure 3-2:  Comparison of microRNA prediction tools ranked by average number of 
predictions per microRNA 
The sensitivity of each microRNA prediction tool was evaluated and plotted against the average 
number of predicted targets per microRNA molecule.  
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Figure 3-2: Comparison of microRNA prediction tools ranked by average number of 
predictions per microRNA 
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Figure 3-3: Comparison of microRNA prediction tools using tissue specific filtration 
Considering tissue specific gene expression increases the sensitivity of all microRNA prediction 
tools and decreases the average number of predicted targets per microRNA molecule. MAPI 
predictions (union of Pictar and Diana Micro T 3.0) offer users the best balance between 
sensitivity and specificity. 62% of all proven interactions are predicted by this combination of 
prediction tools.   
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Figure 3-3: Comparison of microRNA prediction tools using tissue specific filtration 
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the end user is more likely to find an interaction if it exists and they will have a lower number of 
potential targets to evaluate.  
The dataset labeled as MAPI had a sensitivity of over 60%. The only group of predictions 
that had a higher sensitivity was the dataset assembled by considering any target predicted by 
any of the prediction tools (union of all tools). MAPI was able to achieve this level of sensitivity, 
while only predicting 1000 possible targets per microRNA molecule. The dataset assembled from 
all prediction tools predicted an average of 3800 potential targets per microRNA molecule. The 
number of predicted targets per microRNA from MAPI may be more biologically relevant than 
the number achieved by the union of all prediction tools. Previous researchers have suggested 
that each microRNA may regulate up to 500 targets [12]. Inclusion of tissue specific 
transcriptional profiles increases the accuracy of computational prediction methods of microRNA 
target identification.  
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Chapter 4 
Identification of Potential Targets of Human MicroRNA-17-3p Using MAPI
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Identification of potential targets of HSA-miR-17-3p 
 
It was discussed in chapter 1, that the level of human microRNA-17-3p varies in a cancer 
cell progression model and decreases as the cell becomes more tumorigenic. MicroRNA 17-p 
was more abundant in the normal, non-tumorigenic cell line (P69) and markedly decreased in the 
highly tumorigenic, metastatic cell line (M12) but increased in its weakly tumorigenic variant F6 
[24]. It is also known that in patient tumor samples, normal epithelial tissue expresses higher 
levels of miR17-3p than tumor cells [21]. In fact, it was noted that as the Gleason score of cancer 
increases, there is a negative correlation to the level of miR-17-3p. That is as the cancer becomes 
less differentiated and more aggressive, the level of miR-17-3p declines. These observations 
prove that microRNA-17-3p functions as a tumor suppressor in the prostate gland.  
Previous to the start of this work, it was shown that microRNA-17-3p regulates levels of 
vimentin, an intermediate filament protein [22].  It is hypothesized that most microRNAs 
regulate many targets. In order to determine other potential targets of miR-17-3p, we used MAPI 
described in Chapter 3. Priority was given to targets of human microRNA-17-3p that are 
expressed in the prostate gland and proven to be implicated in any form of human cancer (Table 
4-1). Our search revealed two potential targets, insulin growth factor receptor 1 (IGF1R), and the 
Yamaguchi sarcoma viral oncogene homolog 1 (YES1).  Table 4-2 describes the potential targets 
of microRNA-17-3p. 
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Table 4-1: MAPI Search Parameters for Tumorigenic Targets of microRNA-17-3p 
Version 1.0 of the MicroRNA Annotation and Prediction Interface was queried to identify 
potential targets of the tumor suppressing microRNA-17-3p that are expressed in the prostate 
gland. The query options utilized are described in the table.  
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Table 4-1:   MAPI Search Parameters for Tumorigenic Targets of microRNA-17-3p 
Field Parameter 
MicroRNA Human microRNA-17-3p 
Tools PicTar and Diana Micro T 3.0 union 
Cancer related Yes 
Tissue Prostate 
Health State Normal 
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Table 4-2: Potential Targets of Human microRNA-17-3p 
Potential targets of miR17-3p expressed in the prostate gland and implicated in cancer. YES1 is a 
member of the src family and possesses non-receptor tyrosine kinase activity [55].  IGF1R is a 
trans membrane receptor tyrosine kinase implicated in many forms of cancer [56]. 
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Table 4-2: Potential Targets of Human MicroRNA-17-3p 
Gene Refseq ID Chromosome/ 
cytogenetic band 
Function 
Yamaguchi Sarcoma Viral 
Homolog 1(Yes1)[13] 
NM_005433 18p11 src family member/  
non-receptor tyrosine kinase 
Insulin Growth Factor 
Receptor 1 (IGF1R)[13] 
NM_00875 15q26 Binds insulin growth factor and 
results in hypertrophy of cells 
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Structural Analysis of IGF1R and miR-17-3p Dimer 
 
 The 3’UTR of the insulin growth factor receptor gene and the sequence of human  
microRNA-17-3p were submitted to RNAhybrid, a tool for the determination of minimum free 
energy hybridization of long and short RNA molecules [48]. miR-17-3p and IGF1R are able to 
achieve dimerization at -31.7 kcal/mol. It is generally thought that true interactions between 
microRNA and target genes will have a delta G of less than -25.0 kcal/mol. The predicted 
structure has perfect seed region binding with bases 2-8 of the microRNA bound to the 3’ UTR 
of IGF1R. The eighth position has a G:U wobble but all other bases of the seed participate in 
canonical Watson Crick base pair interactions. Two base pairs of the microRNA are unable to 
bind to the gene and loop out. There is significant 3’ compensatory loop interactions of the 
microRNA. The predicted dimer structure appears to satisfy all of the rules identified for 
microRNA/ gene binding. (Figure 4-1a).  
 
Multiple Sequence Alignment of IGF1R 3’ UTRs 
 
 3’ untranslated regions of the IGF1R gene were downloaded using the UCSC genome 
browser [57]. The sequences were compiled into a single fasta formatted file using PERL and 
submitted to the ClustalX program locally [58]. Figure 4-1b shows the regions of the alignment 
that correspond to the predicted binding site of IGF1R.  It is generally thought that cross species 
conservation of nucleotides results from selective pressures to retain a given sequence and 
mutations in highly conserved regions are thought to be fatal. The majority of the 3’ untranslated 
region of a gene is not conserved across multiple species, so regions of conservation have been 
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obviously retained for functional purposes. The predicted binding site of miR-17-3p is highly 
conserved across the species suggesting that this region of the 3’ UTR may be involved in an 
interaction with microRNA-17-3p.  
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Figure 4-1: Multiple Sequence Alignment of IGF1R UTR and Predicted Structure 
A. RNAhybrid predicted structure of microRNA-17-3p and the 3’ UTR of insulin growth 
factor receptor gene [48]. The predicted minimum free energy is -31.7 kcal/ mol. The 
maximum free energy of a true target is generally thought to be -25.0 kcal/ mol. The 
overall structure adheres to all known “rules” observed in previous proven targets.  
B.  IGF1R sequences from human, mouse, rat, dog, and chimpanzee were aligned using 
Clustal X [58]. With the exception of the second base in mice and rats, all bases of the 
seed region are perfectly conserved across all species. Much of the 3’ UTR not shown in 
this figure is not conserved. This implies a selective pressure for this region of the gene. 
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Figure 4-1: Multiple Sequence Alignment of IGF1R UTR and Predicted Structure 
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Structural Analysis of YES1 and miR-17-3p 
 
The sequence of the Yamaguchi Sarcoma Virus Oncogene Homolog was obtained from 
NCBI and submitted to the RNAhybrid program, along with the sequence of human microRNA-
17-3p [48]. The predicted minimum free energy of dimer formation is -22.5 kcal/mol. Bases 2-8 
of the seed region are predicted to bind to the 3’ UTR of the gene, with a G:U wobble at position 
seven of the microRNA. There is a large loop of the UTR and a region of the microRNA that is 
not predicted to bind to the gene. Figure 4-2 shows the predicted structure of the miR and the 
UTR of the YES1 gene. The predicted structure did not support the prediction of YES1 as a 
potential target and it was not investigated further.  
 
Insulin Growth Factor Receptor 1  
 
The insulin growth factor receptor 1 gene imparts a survival advantage, an anchorage 
independent growth advantage to cells and protects cells from apoptosis [56, 59]. Cells that 
express higher levels of IGF1R are shown to be more tumorigenic and metastatic. It is 
hypothesized that increased levels of IGF1R lead to a transformed phenotype that imparts an 
oncogenic potential to the cell.  
Tissue samples extracted from formalin-fixed, paraffin embedded tissue obtained from a 
fine needle biopsy showed higher protein and mRNA levels of IGF1R in primary prostate cancer 
compared to benign prostatic epithelium [59]. Levels of insulin growth factor receptor 1 were 
also shown to increase in the metastatic sites of prostate cancer. Metastasis is accomplished 
because metastasizing cells must detach themselves from other cells in the tissue and mobilize 
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Figure 4-2: Predicted Structure of miR-17-3p and YES1 
RNAhybrid predicted structure of dimer formation between microRNA-17-3p and the 3’ UTR of 
YES1 [48].
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Figure 4-2: Predicted Structure of miR-17-3p and YES1 
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themselves. Vimentin has been shown to correlate with an increased ability of cells to be motile 
and invasive [60].  IGF1R potentially causes an upregulation of extracellular proteases in the 
prostate, imparting an ability of cells to detach from their neighbors [61].  Because of the 
structural prediction, sequence conservation and functional significance, further validation of 
IGF1R was undertaken.  
 
Validation of miR-17-3p and IGF1R Interaction 
 
 In order to validate the regulation of insulin growth factor receptor 1 levels in the 
prostate, protein levels were measured in a prostate cancer cell line [24]. Two sublines were 
chosen for comparison of protein levels. The first is a highly tumorigenic, metastatic cell line 
stably transformed with a plasmid that expresses a non-targeting RNA molecule (M12 +NTC). 
This cell line serves as our negative control. A second set of highly tumorigenic, metastatic cells 
was stably transformed with a plasmid that expresses a functional copy of microRNA-17-3p 
(M12 + miR17-3p) [22]. This cell line is our experimental model.  
 
Cell Culture Methods 
 
 All cells were grown at 37° C in RPMI 1640 growth media containing L-glutamine 
obtained from Sigma-Aldrich and supplemented with 5% fetal bovine serum, 5 μg/ml insulin, 5 
μg/ml transferring, 5 ng/ml selenious acid, (ITS from Collaborative Research Bedford,MA). 
Gentamycin (0.05 mg/ml) was added to inhibit bacterial contamination of culture. Cells 
containing the integrated plasmids were selected by growth in puramycin. All tissue culture cells 
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were grown in 250 ml T75 flasks and split when confluent. Cells were pelleted after trypsin 
digestion by centrifugation at 5000 rpm for five minutes. Cells pellets were washed in 1X PBS 
buffer and re-centrifuged at 5000 rpm for five additional minutes. Following pelleting of the 
cells, cells were flash frozen in liquid nitrogen and stored at -80 ° C. 
  
Western Blot Analysis 
 Cell pellets were thawed on ice and re-suspended in 200 - 400 microliters of 4% SDS in 
PBS after thawing. Cell lysates were prepared by sonication of cell suspension for five minutes. 
Following sonication, cellular debris was removed after dilution of lysate in one volume of PBS 
buffer and centrifugation at 10,000 rpm for five additional minutes. Proteins (50 mg) were 
separated by electrophoresis on a BioRad SDS denaturing 4-14% Tris-HCl gradient gel at 120 
mV for 1.5 hours.  
Separated proteins were transferred to a nitrocellulose membrane and non-specific 
interactions were minimized by blocking the membrane in 3% powdered milk dissolved in TBST 
buffer. IGF1R proteins were visualized using IGF-I receptor beta antibody from Cell Signaling 
Technology and a secondary anti-rabbit antibody.  
Figure 4-3 shows the results of the western blot analysis of the M12 + NTC and M12 + 
miR-17-3p cell lines. Actin was used as an internal control to verify consistency of protein loads. 
Vimentin levels were also analyzed to ensure that the plasmid transcribing miR-17-3p was 
functioning, as it is known that miR-17-3p targets vimentin. Protein levels of IGF1R were 
significantly higher in the M12 + NTC cell line as compared to the levels in the M12 + miR-17-
3p cell line. The level of actin was consistent across both cell lines and the levels of vimentin 
exhibited the expected decrease in expression confirming the increased level of miR-17-3p in the 
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stably transformed M12+miR-17-3p cell line. The decrease in IGF1R levels dependent on miR-
17-3p confirms that IGF1R mRNA is targeted by miR-17-3p. 
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Figure 4-3: Western Blot Analysis of IGF1R Protein Levels 
Whole cell extracts were subjected to Western blot analysis with antibody to IGF1R, actin, or 
vimentin in M12 cells with restored expression of miR-17-3p (M12+ miR-17-3p) compared to 
M12 cells expressing a negative non-targeting RNA control (M12+NTC). Levles of actin are 
consistent in both lanes of the western blot, proving that the load of protein is similar in both 
lanes of the gradient gel. Vimentin levels were analyzed as a positive control, as it has been 
previously shown that miR-17-3p targets vimentin [22].  
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Figure 4-3: Western Blot Analysis of IGF1R Protein Levels 
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Conclusions 
 
 Prostate cancer is a significant problem for men in the United States and across the world. 
MicroRNA proteins are post-transcriptional regulators of protein products that have been shown 
to be involved in numerous cellular processes. MicroRNA dysregulation has been shown to lead 
to the development of several forms of human cancer. Human microRNA-17-3p has been shown 
to be differentially regulated in primary tumors of the prostate and decreases as the Gleason 
score of the tumor increases.  
miR-17-3p has been shown to target the intermediate filament protein vimentin. It is 
hypothesized that most microRNAs target more than one protein. A bioinformatics approach was 
undertaken to elucidate further putative targets of miR-17-3p. A unique comprehensive 
microRNA target prediction tool was designed that harnesses the information inherent in many 
freely available databases and combines them into a single resource. This comprehensive 
database was used to identify other potential targets of miR-17-3p. IGF1R was identified as a 
potential target of the microRNA, which was previously shown to be differentially regulated in 
prostate cancer. Prostate cancer cell lines were utilized to verify regulation of IGF1R by miR-17-
3p. Levels of IGF1R protein varied between the cell lines and was lower in the cell line 
expressing microRNA-17-3p. Based on these experiments, it does indeed appear as if 
microRNA-17-3p regulated the levels of insulin growth factor receptor and the MAPI interface 
was instrumental in identifying this new relevant target for miR-17-3p.  
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